Alert: Major Price Advance (9/10/19)-Revance Therapeutics Inc (NASDAQ: RVNC).

out_altlogo2#71829.jpg

On 9/10/19, Revance Therapeutics Inc (NASDAQ: RVNC) stock enjoyed a major increase of 11.4%, closing at $12.55. Moreover, trading volume in this advance was unusually high at 160% of normal. The stock has been extremely weak relative to the market over the last nine months but has risen 18.4% during the last week.

out_mm#71829.jpg

Current PriceTarget Research Rating

RVNC’s future returns on capital are forecasted to be below the cost of capital. Accordingly, the company is expected to be a major Value Eraser.

Revance Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Revance Therapeutics has a very low Appreciation Score of 7 and a very low Power Rating of 6, leading to the Lowest Value Trend Rating.

Rating Review

In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.

About John Lafferty 80532 Articles
During his career, John has developed valuation and stock rating methodologies, managed institutional portfolios and mutual funds, and provided equity research to institutional investors on thousands of companies. He has been Director of Research at PTR since its inception in 2004.

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.